Welcome to our dedicated page for Scpharmaceutical SEC filings (Ticker: SCPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical trial data, FDA correspondence, and cash-runway projections make scPharmaceuticals’ SEC filings anything but light reading. Finding when officers file scPharmaceuticals insider trading Form 4 transactions or parsing risk disclosures around FUROSCIX often means wading through hundreds of pages.
Stock Titan solves that. Our AI translates dense biotech language into clear takeaways, flagging each scPharmaceuticals quarterly earnings report 10-Q filing within minutes of hitting EDGAR. Whether you need scPharmaceuticals Form 4 insider transactions real-time alerts, a one-page brief on liquidity ratios, or guidance for understanding scPharmaceuticals SEC documents with AI, we surface the essentials so you can focus on decisions, not document mining.
Here’s what you’ll uncover:
- Trial milestones and FDA updates via scPharmaceuticals 8-K material events explained
- Segment spend, revenue outlook, and pipeline costs in each scPharmaceuticals earnings report filing analysis
- Executive pay details from the scPharmaceuticals proxy statement executive compensation
- Real-time alerts on scPharmaceuticals executive stock transactions Form 4
- Full risk-factor commentary in the scPharmaceuticals annual report 10-K simplified
Every filing—10-K, 10-Q, 8-K, Form 4, DEF 14A—is indexed seconds after release, summarized by AI, and paired with expert context. Compare quarter-over-quarter R&D spend, monitor insider sentiment before material news, or track manufacturing agreements without digging through PDFs. Complex biotech disclosures, clarified.
Glazer Capital, LLC and its Managing Member Paul J. Glazer filed a Schedule 13G reporting shared beneficial ownership of 2,474,820 shares of scPharmaceuticals Inc. common stock, representing 4.64% of the class. The filing notes the shares are held by funds and managed accounts for which Glazer Capital serves as investment manager and that the Reporting Persons do not assert sole voting or dispositive power over these shares. The statement also indicates that the Reporting Persons have ceased to be beneficial owners of more than 5% of the class.
scPharmaceuticals received a tender offer from Seacoast Merger Sub, a MannKind subsidiary, to acquire all outstanding shares for $5.35 per share in cash plus one contingent value right (CVR) per share that can pay up to $1.00 in aggregate upon achievement of specified regulatory and net-sales milestones. The Offer and related Letter of Transmittal were filed on the Schedule TO on September 8, 2025. Under the agreed terms the aggregate consideration could be up to $6.35 per share, which the filing says implied approximately a 43% premium to the August 20, 2025 closing price of $4.45. The record summarizes prior indications and competing non-binding proposals, milestone payment schedules tied to SCP-111 FDA approval windows and trailing 12-month net sales, potential impacts from a Device Supplier pricing increase, and customary pre-closing covenants and severance arrangements for executives. The filing also notes HSR/antitrust waiting periods and that the Offer is subject to the conditions specified in the Schedule TO.
The communication states that scPharmaceuticals has initiated a tender offer process and that a Schedule 14D-9 will be filed with the SEC. The offer to purchase scPharmaceuticals common stock will be made only through the formal offer documents filed as part of the Schedule TO, including the offer to purchase and letter of transmittal, and investors are urged to read the tender offer statement and any solicitation/recommendation statement when available. It warns that forward-looking statements involve risks, including integration risks from acquisitions, development and clinical trial timing risks, uncertain milestone payments tied to a contingent value right, and potential adverse effects on Parent's share price if expected benefits are not realized. The filing points readers to www.sec.gov and scPharmaceuticals' Investor Relations page for free copies of related documents.
scPharmaceuticals and Parent plan filings related to a proposed tender offer: a Schedule 14D-9 will be filed by scPharmaceuticals and the offer will be made only via the Offer to Purchase, Letter of Transmittal and related Schedule TO documents. Investors are urged to read the tender offer statement and the solicitation/recommendation statement when available because they will contain important terms and conditions for tendering shares. Free copies of those statements will be available on the SEC website and via the Offer Information Agent, and scPharmaceuticals will post related filings in its Investor Relations section. The communication discloses customary transaction risks, including integration risk, development and clinical timing risks, uncertainty around contingent value right milestone payments, and the possibility that Parents share price could decline if perceived benefits are not realized. Exhibits include internal emails and a LinkedIn announcement dated August 25, 2025.
scPharmaceuticals (SCPH) entered a definitive merger transaction with MannKind Corporation and its merger subsidiary, accompanied by a related press release. The merger agreement dated August 24, 2025, provides that in-the-money Company Options outstanding immediately before the effective time will be cancelled and converted into a cash payment equal to the excess of the cash merger consideration over each option's exercise price plus one contingent value right (CVR) per underlying share. The CVRs will be nontransferable except for limited exceptions and a register of CVR holders will be maintained. The filing includes typical deal protections restricting the Company from soliciting or recommending alternative acquisition proposals, subject to board fiduciary duties. The document references SEC filings and risk factor disclosures.
scPharmaceuticals Inc. filed an 8-K reporting an amendment to a supply agreement: Amendment 1 to the Supply Agreement dated August 20, 2025 between West Pharmaceutical Services, Inc. and the registrant. The filing includes a cover page interactive data file embedded in the inline XBRL document and is signed by John H. Tucker, President and Chief Executive Officer of scPharmaceuticals Inc.
The filing identifies the amendment document and the parties but does not provide the amendment's financial terms, operational changes, or material effects on the company within the provided excerpt.
FAQ
What is the current stock price of Scpharmaceutical (SCPH)?
What is the market cap of Scpharmaceutical (SCPH)?
